Mounjaro's Sales Likely To Rise 2.5x Driving Eli Lilly's Q3 Performance
LLYLilly(LLY) Forbes·2024-10-29 01:36

Eli Lilly logo is screened on a mobile phone for illustration photo. Krakow, Poland on April 9th, ... [+] 2024 (Photo by Beata Zawrzel/NurPhoto via Getty Images) NurPhoto via Getty Images Eli Lilly stock (NYSE: LLY) will report its Q3 results on Wednesday, October 30. The pharmaceutical giant is expected to garner $12.1 billion in sales and $1.45 in adjusted earnings per share, per the consensus estimates. All eyes will be on Eli Lilly's diabetes drug – Mounjaro – and its weight-loss drug – Zepbound. In thi ...